Biohaven Ltd is a biopharmaceutical company based in New Haven, Connecticut, dedicated to advancing treatments in immunology, neuroscience, and oncology. With a robust pipeline, Biohaven is actively working on developing therapies for a range of conditions including neurological disorders, spinal muscular atrophy, obesity, epilepsy, bipolar disorder, major depressive disorder, migraines, neuropathic pain, Alzheimer's, Parkinson’s disease, rheumatoid arthritis, and various cancers. The company collaborates with prestigious institutions like Yale University and AstraZeneca to bring innovative solutions from the lab to the patients who need them.